PL EN


Preferences help
enabled [disable] Abstract
Number of results
2017 | 64 | 2 | 307-313
Article title

Anticancer activity of some polyamine derivatives on human prostate and breast cancer cell lines

Content
Title variants
Languages of publication
EN
Abstracts
EN
The aim of this study was to expand our knowledge about anticancer activity of some polyamine derivatives with quinoline or chromane as terminal moieties. Tested compounds were evaluated in vitro towards metastatic human prostate adenocarcinoma (PC3), human carcinoma (DU145) and mammary gland adenocarcinoma (MCF7) cell lines. Cell viability was estimated on the basis of mitochondrial metabolic activity using water-soluble tetrazolium WST1 to establish effective concentrations of the tested compounds under experimental conditions. Cytotoxic potential of polyamine derivatives was determined by the measurement of lactate dehydrogenase activity released from damaged cells, changes in mitochondrial membrane potential, the cell cycle distribution analysis and apoptosis assay. It was revealed that the tested polyamine derivatives differed markedly in their antiproliferative activity. Bischromane derivative 5a exhibited a rather cytostatic than cytotoxic effect on the tested cells, whereas quinoline derivative 3a caused changes in cell membrane integrity, inhibited cell cycle progression, as well as induced apoptosis of prostate and breast cancer cells which suggest its potential application in cancer therapy.
Year
Volume
64
Issue
2
Pages
307-313
Physical description
Dates
published
2017
received
2016-08-24
revised
2016-12-21
accepted
2016-12-28
(unknown)
2017-04-14
References
  • Brana MF, Cacho M, Gradillas A, de Pascual-Teresa B, Ramos A (2001) Intercalators as anticancer drugs. Curr Pharm Des 7: 1745-1780. doi: 10.2174/1381612013397113.
  • Burns MR, LaTurner S, Ziemer J, McVean M, Devens B, Carlson CL, Graminski GF, Vanderwerf SM, Weeks RS, Carreon J (2002) Induction of apoptosis by aryl-substituted diamines: role of aromatic group substituents and distance between nitrogens. Bioorg Med Chem Lett 12: 1263-1267. doi: 10.1016/S0960-894X(02)00156-7.
  • Deady LW, Kaye AJ, Finlay GJ, Baguley BC, Denny WA (1997) Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors. J Med Chem 40: 2040-2046. doi: 10.1021/jm970044r.
  • Dominska K, Piastowska-Ciesielska AW, Lachowicz-Ochedalska A, Ochedalski T (2012) Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation. Peptides 37: 200-206. doi: 10.1016/j.peptides.2012.07.022.
  • Ellem SJ, De-Juan-Pardo EM, Risbridger GP (2014) In vitro modeling of the prostate cancer microenvironment. Adv Drug Deliv Rev 79-80: 214–221. doi: 10.1016/j.addr.2014.04.008.
  • Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, Wolfe C, Hamadeh RR, Moore A, Werdecker A, Gessner BD, Te Ao B, McMahon B, Karimkhani C, Yu C, Cooke GS, Schwebel DC, Carpenter DO, Pereira DM, Nash D, Kazi DS, De Leo D, Plass D, Ukwaja KN, Thurston GD, Yun Jin K, Simard EP, Mills E, Park EK, Catalá-López F, deVeber G, Gotay C, Khan G, Hosgood HD 3rd, Santos IS, Leasher JL, Singh J, Leigh J, Jonas JB, Sanabria J, Beardsley J, Jacobsen KH, Takahashi K, Franklin RC, Ronfani L, Montico M, Naldi L, Tonelli M, Geleijnse J, Petzold M, Shrime MG, Younis M, Yonemoto N, Breitborde N, Yip P, Pourmalek F, Lotufo PA, Esteghamati A, Hankey GJ, Ali R, Lunevicius R, Malekzadeh R, Dellavalle R, Weintraub R, Lucas R, Hay R, Rojas-Rueda D, Westerman R, Sepanlou SG, Nolte S, Patten S, Weichenthal S, Abera SF, Fereshtehnejad SM, Shiue I, Driscoll T, Vasankari T, Alsharif U, Rahimi-Movaghar V, Vlassov VV, Marcenes WS, Mekonnen W, Melaku YA, Yano Y, Artaman A, Campos I, MacLachlan J, Mueller U, Kim D, Trillini M, Eshrati B, Williams HC, Shibuya K, Dandona R, Murthy K, Cowie B, Amare AT, Antonio CA, Castañeda-Orjuela C, van Gool CH, Violante F, Oh IH, Deribe K, Soreide K, Knibbs L, Kereselidze M, Green M, Cardenas R, Roy N, Tillmann T, Li Y, Krueger H, Monasta L, Dey S, Sheikhbahaei S, Hafezi-Nejad N, Kumar GA, Sreeramareddy CT, Dandona L, Wang H, Vollset SE, Mokdad A, Salomon JA, Lozano R, Vos T, Forouzanfar M, Lopez A, Murray C, Naghavi M (2015) The Global Burden of Cancer 2013. JAMA Oncol 1: 505-527. doi: doi:10.1001/jamaoncol.2015.0735.
  • Hansch C, Verma RP (2007) 20-(S)-camptothecin analogues as DNA topoisomerase I inhibitors: a QSAR study. Chem Med Chem 2: 1807-1813. doi: 10.1002/cmdc.200700138.
  • Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90. doi: 10.3322/caac.20107.
  • Latosinska JN, Latosinska M (2013) Anticancer drug discovery - from serendipity to rational design. Drug Discovery. Hany El-Shemy. ISBN 978-953-51-0906-8. http://cdn.intechopen.com/pdfs-wm/41943.pdf
  • Li HJ, Li XJ, Bai ML, Suo YE, Zhang GH, Cao XY (2015) Matrine inhibited proliferation and increased apoptosis in human breast cancer MCF-7 cells via upregulation of Bax and downregulation of Bcl-2. Int J Clin Exp Pathol 8: 14793-14799.
  • Li K, Li Y, Zhou D, Fan Y, Guo H, Ma T, Wen J, Liu D, Zhao L (2016) Synthesis and biological evaluation of quinoline derivatives as potential anti-prostate cancer agents and Pim-1 kinase inhibitors. Bioorg Med Chem 24: 1889-1897. doi: 10.1016/j.bmc.2016.03.016.
  • Lorente A, Vázquez Y, Fernández MJ, Ferrández A (2004) Bisacridines with aromatic linking chains. Synthesis, DNA interaction, and antitumor activity. Bioorg Med Chem 12: 4307-4312 doi: 10.1016/j.bmc.2004.06.021.
  • Ma WW, Adjei AA (2009) Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59: 111-137. doi: 111-137. 10.3322/caac.20003.
  • Ming J, Ruan S, Wang M, Ye D, Fan N, Meng Q, Tian B, Huang T (2015) A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1. Oncotarget 6: 40692-40703. doi: 10.18632/oncotarget.5827.
  • Nawrot-Modranka J, Nawrot E, Graczyk J (2006) In vivo antitumor, in vitro antibacterial activity and alkylating properties of phosphorohydrazine derivatives of coumarin and chromone. Eur J Med Chem 41: 1301-1309. doi: 10.1016/j.ejmech.2006.06.004.
  • Piastowska-Ciesielska AW, Kozlowski M, Wagner W, Dominska K, Ochedalski T (2013) Effect of an angiotensin II type 1 receptor blocker on caveolin-1 expression in prostate cancer cells. Arch Med Sci 9: 739-744. doi: 10.5114/aoms.2012.30955.
  • Rescifina A, Zagni C, Varrica MG, Pistara V, Corsaro A (2014) Recent advances in small organic molecules as DNA intercalating agents: synthesis, activity, and modeling. Eur J Med Chem 74: 95-115. doi: 10.1016/j.ejmech.2013.11.029.
  • Rawat RP, Verma SM (2016) Design and synthesis of chroman derivatives with dual anti-breast cancer and antiepileptic activities. Drug Des Devel Ther 10: 2779-2788. doi: 10.2147/DDDT.S111266.
  • Sahu U, Sidhar H, Ghate PS, Advirao GM, Raghavan SC, Giri RK (2013) A novel anticancer agent, 8-methoxypyrimido[4',5':4,5]thieno(2,3-b) quinoline-4(3H)-one induces neuro 2a neuroblastoma cell death through P53-dependent, caspase-dependent and -independent apoptotic pathways. PLoS One 8: e66430. doi: 10.1371/journal.pone.0066430.
  • Saleh AM, Aljada A, El-Abadelah MM, Sabri SS, Zahra JA, Nasr A, Aziz MA (2015a) The pyridone-annelated isoindigo (5'-Cl) induces apoptosis, dysregulation of mitochondria and formation of ROS in leukemic HL-60 cells. Cell Physiol Biochem 35: 1958-1974. doi: 10.1159/000374004.
  • Saleh AM, El-Abadelah MM, Aziz MA, Taha MO, Nasr A, Rizvi SA (2015b) Antiproliferative activity of the isoindigo 5'-Br in HL-60 cells is mediated by apoptosis, dysregulation of mitochondrial functions and arresting cell cycle at G0/G1 phase. Cancer Lett 361: 251-261. doi: 10.1016/j.canlet.2015.03.013.
  • Sampson N, Neuwirt H, Puhr M, Klocker H, Eder IE (2013) In vitro model systems to study androgen receptor signaling in prostate cancer. Endocr Relat Cancer 20: R49-R64. doi: 10.1530/ERC-12-0401.
  • Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63: 11-30. doi: 10.3322/caac.21166.
  • Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66: 7-30. doi: 10.3322/caac.21332.
  • Szulawska-Mroczek A, Szumilak M, Szczesio M, Olczak A, Nazarski RB, Lewgowd W, Czyz M, Stanczak A (2013) Synthesis and biological evaluation of new bischromone derivatives with antiproliferative activity. Arch Pharm (Weinheim) 346: 34-43. doi: 10.1002/ardp.201200220.
  • Szumilak M, Szulawska-Mroczek A, Koprowska K, Stasiak M, Lewgowd W, Stanczak A, Czyz M (2010) Synthesis and in vitro biological evaluation of new polyamine conjugates as potential anticancer drugs. Eur J Med Chem 45: 5744-5751. doi: 10.1016/j.ejmech.2010.09.032.
  • Taher AT, Hegazy GH (2013) Synthesis of novel bis-anthraquinone derivatives and their biological evaluation as antitumor agents. Arch Pharm Res 36: 573-578. doi: 10.1007/s12272-013-0074-x.
  • Trathnigg B, Golob K, Junek H, Popitsch A (1985) Chelating enaminoketones, II. Syntheses of symmetric ligands. Monatsh Chem 116: 323-339
  • Tse WC, Boger DL (2004) Sequence-selective DNA recognition: natural products and nature's lessons. Chem Biol 11: 1607-1617. doi: 10.1016/j.chembiol.2003.08.012.
  • Walczak JR, Carducci MA (2007) Prostate cancer: a practical approach to current management of recurrent disease. Mayo Clin Proc 82: 243-249. doi: 10.4065/82.2.243.
  • Wojciechowska U, Didkowska J (2013) Illness and deaths from malignant tumors in Poland. National Cancer Registry, Cancer Centre - Institute for them. Maria Sklodowska-Curie. ISSN 0867-8251. http://onkologia.org.pl/wp-content/uploads/BIUL2013.pdf
  • Xiong P, Wang R, Zhang X, DeLa TE, Leon F, Zhang Q, Zheng S, Wang G, Chen QH (2015) Design, synthesis, and evaluation of genistein analogues as anti-cancer agents. Anticancer Agents Med Chem 15: 1197-1203. doi: 10.2174/1871520615666150520142437.
  • Xu L, Farmer R, Huang X, Pavese J, Voll E, Irene O, Biddle M, Nibbs A, Valsecchi M, Scheidt K, Bergan R (2010) Discovery of a novel drug KBU2046 that inhibits conversion of human prostate cancer to a metastatic phenotype. Cancer Prev Res 3 (12 Suppl): B58 doi: 10.1158/1940-6207.PREV-10-B58
Document Type
Publication order reference
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv64p307kz
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.